Phathom Pharmaceuticals Overview
Phathom Pharmaceuticals Target Price
Analysts' 12-month price predictions for PHAT.
Get informed when a big investor buys or sells
+ FollowShare Price
$11.04
Average Target Price
$18.00
63.1% upside
63.1% upside1 analysts in the last 4 months
High: $18 | Low: $18
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-03-27 | BarclaysJenna Davidner | $18 | 63.1% upside |  |
| 2026-02-26 | Stifel NicolausAnnabel Samimy | $28 | 153.7% upside | |
| 2025-12-11 | Raymond JamesMartin Auster | $28 | 153.7% upside | |
| 2025-12-08 | BarclaysJenna Davidner | $16 | 45% upside | |
| 2025-10-31 | Craig-HallumChase Knickerbocker | $22 | 99.4% upside | |
| 2025-10-31 | H.C. Wainwright | $26 | 135.6% upside | |
| 2025-10-30 | GuggenheimYatin Suneja | $20 | 81.2% upside | |
| 2025-03-07 | Guggenheim | $18 | 63.1% upside | |
| 2024-08-08 | Goldman SachsPaul Choi | $12 | 8.7% upside | |
| 2024-07-19 | H.C. WainwrightMatthew Caufield | $28 | 153.7% upside | |
| 2024-05-02 | Stifel NicolausAnnabel Samimy | $24 | 117.5% upside | |
| 2024-01-05 | NeedhamJoseph Stringer | $26 | 135.6% upside | |
| 2023-01-04 | BMO Capital | $35 | 217.2% upside | |
| 2023-01-04 | Needham | $25 | 126.6% upside | |
| 2022-11-14 | BMO Capital | $38 | 244.4% upside | |
| 2022-11-11 | Guggenheim | $30 | 171.9% upside | |